Wolverine Asset Management’s Sinovac Biotech SVA Stock Holding History
Bought
Maintained
Sold
Other funds holding SVA
NAH
Wolverine Asset Management's SVA Position: Q4 2017 in Review
Wolverine Asset Management sold out of Sinovac Biotech (SVA) in Q4 2017, closing a stake of 99,212 shares — an estimated $699K sold.
Wolverine Asset Management first reported a position in SVA in Q2 2017 and held it in 2 quarters. The position peaked at $699K in Q3 2017. 31 funds tracked by Wall St. Rank hold SVA as of Q4 2017.
- Wolverine Asset Management reported no remaining Sinovac Biotech position as of Q4 2017 after selling out during the quarter.
- Wolverine Asset Management sold 99,212 Sinovac Biotech shares in Q4 2017, an estimated $699K.
- Wolverine Asset Management first reported a position in Sinovac Biotech in Q2 2017 and held it in 2 quarters.
- Wolverine Asset Management's Sinovac Biotech position peaked at $699K in Q3 2017.
- 31 funds tracked by Wall St. Rank held Sinovac Biotech as of Q4 2017.
Based on Wolverine Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.